9 unknown. 9 Phase 1, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 9 | Unknown 9 |
| Phase 2 | 5 | Unknown 5 |
Follow Mantle Cell Lymphoma: new trials by email Literature Review of Mantle Cell Lymphoma trials Research Report on Mantle Cell Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| PSB202 in Patients With Previously Treated-, Relapsed-, Indolent B-Cell Malignancies PSB202 - Follicular Lymphoma, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Phase 1 | Unknown | Qilu Puget Sound Biotherapeutics (dba Sound Biologics) | 110 | 2021-11-15 | 2022-03-28 |
| First in Human Study of NVG-111 in Relapsed/Refractory ROR1+ Malignancies NVG-111 - Chronic Lymphocytic Leukaemia, Small Lymphocytic Lymphoma | Phase 1 | Unknown | NovalGen Ltd. | 90 | 2021-05-14 | 2023-07-07 |
| A Clinical Research of CD22-Targeted CAR-T in B Cell Malignancies Autologous chimeric antigen receptor T cell transfusing agent targeting CD22 - Diffuse Large B Cell Lymphoma, Follicular Lymphoma | Phase 1 | Unknown | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | 10 | 2018-12-01 | 2019-06-27 |
| CAR-T Cell Immunotherapy in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma PCAR-019 (anti-CD19 CAR-T cells) - Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | Unknown | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | 10 | 2016-10-01 | 2016-10-25 |
| PCAR-119 Bridge Immunotherapy Prior to Stem Cell Transplant in Treating Patients With CD19 Positive Leukemia and Lymphoma anti-CD19 CAR-NK cells - Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | Unknown | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | 10 | 2016-09-01 | 2016-12-06 |
| Study Evaluating the Efficacy and Safety of PCAR-019 in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma PCAR-019 (anti-CD19 CAR-T cells) - Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | Unknown | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | 10 | 2016-07-01 | 2016-08-01 |
| Ixazomib & Rituximab After Stem Cell Transplant in Treating Patients With Mantle Cell Lymphoma in Remission Ixazomib, Rituximab - Mantle Cell Lymphoma | Phase 1 / Phase 2 | Unknown | Emory University | 12 | 2016-03-01 | 2023-05-09 |
| CART-19 Immunotherapy in Mantle Cell Lymphoma anti-CD19-CAR vector-transduced T cells - Hematopoietic/Lymphoid Cancer, Non-hodgkin Lymphoma,B Cell | Phase 1 / Phase 2 | Unknown | Chinese PLA General Hospital | 2 | 2014-03-01 | 2014-03-11 |
| Bortezomib (VELCADE), Cladribine and Rituximab (VCR) in Mantle Cell Lymphoma (PSHCI 10-011) Rituximab, bortezomib, Cladribine - Mantle Cell Lymphoma | Phase 1 | Unknown | Milton S. Hershey Medical Center | 13 | 2012-05-01 | 2017-08-07 |
Lymphoma, Mantle-Cell (9) · Lymphoma, Follicular (6) · Leukemia, Lymphocytic, Chronic, B-Cell (5) · Lymphoma, Large B-Cell, Diffuse (5) · Leukemia, Prolymphocytic, B-Cell (3) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (3) · Lymphoma, B-Cell (2) · Lymphoma, B-Cell, Marginal Zone (2) · Carcinoma, Non-Small-Cell Lung (1) · Hematologic Neoplasms (1) · Leukemia, B-Cell (1) · Lymphoma (1) · Melanoma (1) · Neoplasms, Plasma Cell (1) · Waldenstrom Macroglobulinemia (1)
Hemic and Lymphatic Diseases (9) · Immune System Diseases (9) · Immunoproliferative Disorders (9) · Lymphatic Diseases (9) · Lymphoma, Non-Hodgkin (9) · Lymphoproliferative Disorders (9) · Neoplasms (9) · Neoplasms by Histologic Type (9) · Lymphoma (8) · Hematologic Diseases (6) · Chronic Disease (5) · Disease Attributes (5) · Leukemia (5) · Leukemia, Lymphoid (5) · Pathologic Processes (5)
Antigens, CD19 (3) · Sensitivity and Specificity (3) · Immunotherapy, Adoptive (2) · Rituximab (2) · Bortezomib (1) · Cladribine (1) · ixazomib (1)
PersonGen BioTherapeutics (Suzhou) Co., Ltd. (4) · Chinese PLA General Hospital (1) · Emory University (1) · Milton S. Hershey Medical Center (1) · NovalGen Ltd. (1) · Qilu Puget Sound Biotherapeutics (dba Sound Biologics) (1)
China (6) · United States (3) · Australia (1) · United Kingdom (1)
Jeffrey J Pu, MD PhD (1) · Jonathon Cohen, MD, MS (1) · Lin Yang, Ph.D. (1) · Lindsey E. Roeker, MD (1) · Parag Jasani, MBBS, FRCP, FRCPath (1) · Xin Liu, Ph.D. (1) · Xingbing Wang, Ph.D. (1)
PMID 28054442, PMID 34515338, PMID 36180329, PMID 39737396, PMID 42216090
P30CA138292 (1)